Emcure Pharmaceuticals Share Price

Audio recording of Earnings Call - Q2 FY27

• BSE India
• 7 hours 36 minutes ago

The company recorded a strong 34 per cent growth in international business to 1,665.2 crore during the quarter while its domestic business rose 11.1 per cent to 1,155.3 crore

• Business Standard
• 9 hours 33 minutes ago

<h3><span style="font-size:16px;"><strong>Pharmaceuticals company Emcure Pharmaceuticals announced Q2FY27 results</strong></span><br /> <!--TgQPHd|||[[2,[null,null,1,null,null,null,null,null,null,null,null,null,[351768,null,0]],[],null,1]]--></h3> <p><!--TgQPHd|||[]--></p> <p><strong>Standalone Financial Highlights:</strong><!--TgQPHd|||[[2,[null,null,1,null,null,null,null,null,null,null,null,null,[351768,null,0]],[],null,1]]--></p> <ul data-complete="true" data-hveid="CAAIChAA" data-processed="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="wiLEJc#NS0kde" jsuid="QgVIIf_1e"> <li data-complete="true" data-hveid="CAAIChAB" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="QgVIIf_1f"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="QgVIIf_1h">Revenue from Operations:<!--TgQPHd|||[]--></strong> For Q2FY27, Standalone Revenue from Operations reached Rs 16,679.84 million, reflecting a sequential expansion of 14.96% QoQ from Rs 14,509.31 million in Q1FY27 and a notable YoY expansion of 32.32% compared to Rs 12,606.04 million in Q2FY26. For H1FY27, it reached Rs 31,189.15 million, growing 32.32% YoY from Rs 23,571.77 million in H1FY26.<!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAIChAE" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="QgVIIf_1n"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="QgVIIf_1p">Total Income:<!--TgQPHd|||[]--></strong> For Q2FY27, Total Income stood at Rs 17,015.22 million, picking up 15.28% QoQ from Rs 14,759.63 million in Q1FY27 and increasing 32.58% YoY from Rs 12,833.57 million in Q2FY26. For H1FY27, it logged Rs 31,774.85 million, marking a 32.32% increase YoY over Rs 24,014.54 million in H1FY26.<!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAIChAH" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="QgVIIf_1v"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="QgVIIf_1x">Profit Before Tax (PBT):<!--TgQPHd|||[]--></strong> For Q2FY27, PBT reached Rs 3,323.76 million, climbing 23.71% QoQ from Rs 2,686.73 million in Q1FY27 and expanding 110.51% YoY from Rs 1,578.91 million in Q2FY26. For H1FY27, Standalone PBT was Rs 6,010.49 million, reflecting an 83.77% increase YoY from Rs 3,270.60 million (before exceptional items) or an 85.76% increase YoY from Rs 3,235.60 million (after exceptional items) in H1FY26.<!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAIChAK" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="QgVIIf_23"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="QgVIIf_25">Profit After Tax (PAT):<!--TgQPHd|||[]--></strong> For Q2FY27, Standalone PAT stood at Rs 2,484.28 million, up sequentially by 24.15% QoQ compared to Rs 2,001.08 million in Q1FY27 and expanding 111.21% YoY against Rs 1,176.22 million in Q2FY26. For H1FY27, PAT stood at Rs 4,485.36 million, increasing 86.57% YoY from Rs 2,404.11 million in H1FY26.<!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAIChAN" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="QgVIIf_2b"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="QgVIIf_2d">Earnings Per Share (EPS):<!--TgQPHd|||[]--></strong> For Q2FY27, Basic EPS stood at Rs 13.10 and Diluted EPS stood at Rs 13.08, growing 24.17% QoQ and 23.98% QoQ from Rs 10.55 in Q1FY27, and gaining 110.95% YoY and 110.63% YoY over Rs 6.21 in Q2FY26. For H1FY27, Basic EPS reached Rs 23.65 and Diluted EPS reached Rs 23.62, expanding 86.37% YoY and 86.13% YoY from Rs 12.69 in H1FY26.<!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <!--TgQPHd|||[]--> </ul> <p><!--TgQPHd|||[]--></p> <p><strong>Consolidated Financial Highlights:</strong><!--TgQPHd|||[[2,[null,null,1,null,null,null,null,null,null,null,null,null,[351768,null,0]],[],null,1]]--></p> <ul data-complete="true" data-hveid="CAAIDBAA" data-processed="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="wiLEJc#NS0kde" jsuid="QgVIIf_2l"> <li data-complete="true" data-hveid="CAAIDBAB" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="QgVIIf_2m"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="QgVIIf_2o">Revenue from Operations:<!--TgQPHd|||[]--></strong> For Q2FY27, Consolidated Revenue from Operations was Rs 28,204.71 million, a sequential jump of 9.30% QoQ from Rs 25,804.47 million in Q1FY27 and an increase of 24.26% YoY compared to Rs 22,698.22 million in Q2FY26. For H1FY27, it totaled Rs 54,009.18 million, marking a 23.58% expansion YoY from Rs 43,703.59 million in H1FY26.<!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAIDBAE" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="QgVIIf_2u"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="QgVIIf_2w">Total Income:<!--TgQPHd|||[]--></strong> For Q2FY27, Total Income stood at Rs 28,237.25 million, growing 9.34% QoQ from Rs 25,825.18 million in Q1FY27 and expanding 24.23% YoY against Rs 22,729.45 million in Q2FY26. For H1FY27, Total Income stood at Rs 54,062.43 million, a 23.51% jump YoY compared to Rs 43,771.78 million in H1FY26.<!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAIDBAH" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="QgVIIf_32"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="QgVIIf_34">Profit Before Tax (PBT):<!--TgQPHd|||[]--></strong> For Q2FY27, Consolidated PBT reached Rs 4,458.52 million (reported as Rs 4,459 million in the press release), up 13.30% QoQ from Rs 3,935.26 million in Q1FY27 and accelerating 30.59% YoY from Rs 3,414.17 million in Q2FY26. For H1FY27, PBT scaled up by 32.12% YoY to Rs 8,393.78 million over Rs 6,353.75 million (before exceptional items) or up 32.78% YoY over Rs 6,321.75 million (after exceptional items) in H1FY26.<!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAIDBAK" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="QgVIIf_3a"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="QgVIIf_3c">Profit After Tax (PAT):<!--TgQPHd|||[]--></strong> For Q2FY27, Consolidated PAT reached Rs 3,250.68 million (reported as Rs 3,251 million in the press release), up 11.14% QoQ from Rs 2,924.93 million in Q1FY27 and up 29.32% YoY over Rs 2,513.70 million in Q2FY26. For H1FY27, PAT expanded 32.48% YoY to Rs 6,175.61 million compared to Rs 4,661.63 million in H1FY26.<!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAIDBAN" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="QgVIIf_3i"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="QgVIIf_3k">Earnings Per Share (EPS):<!--TgQPHd|||[]--></strong> For Q2FY27, Basic EPS came in at Rs 17.16 and Diluted EPS came in at Rs 17.14, increasing 10.71% QoQ and 10.58% QoQ against Rs 15.50 in Q1FY27 and expanding 33.54% YoY and 33.39% YoY from Rs 12.85 in Q2FY26. For H1FY27, Basic EPS expanded 37.44% YoY to Rs 32.67 and Diluted EPS expanded 37.27% YoY to Rs 32.63 from Rs 23.77 in H1FY26.<!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <!--TgQPHd|||[]--> </ul> <p><!--TgQPHd|||[]--></p> <p><!--TgQPHd|||[]--></p> <p><strong>Business Highlights:</strong><br /> <!--TgQPHd|||[]--><!--TgQPHd|||[]--></p> <p><!--TgQPHd|||[]--></p> <ul data-complete="true" data-hveid="CAAIEBAA" data-processed="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="wiLEJc#NS0kde" jsuid="QgVIIf_3w"> <li data-complete="true" data-hveid="CAAIEBAE" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="QgVIIf_45"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="QgVIIf_47">Domestic Business:<!--TgQPHd|||[]--></strong> Domestic sales for Q2FY27 grew 12.0% YoY to Rs 11,553 million, accounting for 41.0% of consolidated revenue. For H1FY27, domestic sales reached Rs 22,506 million, up 11.1% YoY. Growth was led by the Women’s Health franchise, Cardio-Metabolics, and the CNS range, supported by improved traction in Poviztra.<!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAIEBAH" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="QgVIIf_4d"><strong data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="tP2kf#s32ZS" jsuid="QgVIIf_4f">International Business:<!--TgQPHd|||[]--></strong> International sales for Q2FY27 grew 34.5% YoY to Rs 16,652 million, accounting for 59.0% of consolidated revenue. For H1FY27, international sales reached Rs 31,503 million, up 34.5% YoY.<!--TgQPHd|||[]--><!--TgQPHd|||[]--> <ul data-complete="true" data-hveid="CAAIEBAI" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="wiLEJc#NS0kde" jsuid="QgVIIf_4g"> <li data-complete="true" data-hveid="CAAIEBAJ" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="QgVIIf_4h"><strong><em data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="LFsGHb#ycPkjf" jsuid="QgVIIf_4j">Europe:</em></strong><em data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="LFsGHb#ycPkjf" jsuid="QgVIIf_4j"><!--TgQPHd|||[]--></em> Grew 36.0% YoY to Rs 6,043 Mn in Q2FY27, supported by strong delivery across the UK and continental Europe, aided by the continued scale-up of Liposomal Amphotericin B.<!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAIEBAK" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="QgVIIf_4k"><strong><em data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="LFsGHb#ycPkjf" jsuid="QgVIIf_4m">Canada:</em></strong><em data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="LFsGHb#ycPkjf" jsuid="QgVIIf_4m"><!--TgQPHd|||[]--></em> Grew 24.0% YoY to Rs 4,312 Mn in Q2FY27, driven by continued growth in the base business and recent launches.<!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> <li data-complete="true" data-hveid="CAAIEBAL" data-sae="" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="oSLmPe#HokZ0d" jsuid="QgVIIf_4n"><strong><em data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="LFsGHb#ycPkjf" jsuid="QgVIIf_4p">Rest of World (RoW):</em></strong><em data-complete="true" data-sfc-cp="" data-sfc-root="c" jsaction="" jscontroller="LFsGHb#ycPkjf" jsuid="QgVIIf_4p"><!--TgQPHd|||[]--></em> Grew 41.1% YoY to Rs 6,297 Mn in Q2FY27. The ARV business continued its strong performance, while non-ARV growth accelerated, supported by new launches and portfolio expansion across Latin America, CIS, Asia, and Africa markets.<!--TgQPHd|||[]--><!--TgQPHd|||[]--><!--TgQPHd|||[]--></li> </ul> </li> </ul> <p><strong>Satish Mehta, Chairman, Managing Director & CEO, Emcure Pharmaceuticals, said:</strong> " Q2 was another strong quarter for Emcure, with broad-based growth in revenue, profitability and earnings.</p> <p>Revenue grew 24% YoY to Rs 28,205 million, with India growing 12% and International 34.5%. EBITDA grew 31% to Rs  5,748 million, with margin at 20.4%, an expansion of about 100 basis points, driven by productivity gains and operating leverage. PAT grew 29% to Rs 3,251 million. We expect business momentum to sustain into H2FY27.”</p> <p><a class="lb" href="/get-document/post/pdf/5925837/" target="_blank">Result PDF</a></p>

• Trendlyne
• 11 hours 57 minutes ago